Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147591 | 0.88 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ALDH1A1MAPTMEN1 | |
| SCHEMBL10147481 | 0.86 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1GAARAB9AALDH1A1 | |
| SCHEMBL656790 | 0.85 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1GAARAB9AMAPT | |
| SCHEMBL7893313 | 0.83 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1GAARAB9AMAPT | |
| SCHEMBL656515 | 0.82 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1GAARAB9AMAPT | |
| SCHEMBL7885618 | 0.81 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1GAARAB9AMAPT | |
| SCHEMBL656954 | 0.80 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1GAARAB9AALDH1A1 | |
| SCHEMBL655367 | 0.79 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1GAARAB9AALDH1A1 | |
| SCHEMBL10147497 | 0.76 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1MAPTMEN1KMT2A | |
| SCHEMBL655248 | 0.74 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885GAA 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.